Bulletin
Investor Alert

CymaBay Therapeutics Inc.

NAS: CBAY

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 10, 2020, 5:54 p.m.

/zigman2/quotes/201917619/composite

$

3.47

Change

0.00 0.00%

Volume

Volume 2,783

Quotes are delayed by 20 min

/zigman2/quotes/201917619/composite

Previous close

$ 3.34

$ 3.47

Change

+0.13 +3.89%

Day low

Day high

$3.16

$3.48

Open

52 week low

52 week high

$1.21

$6.81

Open

Company Description

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver di...

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Valuation

Price to Book Ratio

0.72

Enterprise Value to EBITDA

0.65

Total Debt to Enterprise Value

-0.04

Efficiency

Income Per Employee

-1,713,467.00

Liquidity

Current Ratio

11.51

Quick Ratio

11.51

Cash Ratio

10.83

Profitability

Return on Assets

-52.39

Return on Equity

-57.63

Return on Total Capital

-57.44

Return on Invested Capital

-57.35

Capital Structure

Total Debt to Total Equity

1.15

Total Debt to Total Capital

1.14

Total Debt to Total Assets

1.05

Long-Term Debt to Equity

0.94

Long-Term Debt to Total Capital

0.92

Officers and Executives

Name Age Officer Since Title
Dr. Charles A. McWherter 64 2007 Senior Vice President-Research
Mr. Patrick J. O'Mara 57 1991 Vice President-Business Development
Ms. Klara A. Dickinson-Eason 52 2017 Chief Regulatory & Compliance Officer
Mr. Daniel Menold 49 2014 Controller
Dr. Patricia Rohane - 2018 Vice President-Clinical Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
10/10/2019 Sujal Shah
Chief Executive Officer; Director
5,000   Acquisition at $4.3 per share. 21,500
09/23/2019 Sujal Shah
Chief Executive Officer; Director
3,100   Acquisition at $5.55 per share. 17,205
09/20/2019 Sujal Shah
Chief Executive Officer; Director
1,900   Acquisition at $5.5 per share. 10,450
02/07/2019 Carl Samuel Goldfischer
Director
11,675   Disposition at $9.02 per share. 105,308
02/07/2019 Carl Samuel Goldfischer
Director
9,340   Derivative/Non-derivative trans. at $5.5 per share. 51,370
02/07/2019 Carl Samuel Goldfischer
Director
2,335   Derivative/Non-derivative trans. at $5 per share. 11,675
12/21/2018 Sujal Shah
Chief Executive Officer; Director
10,000   Acquisition at $6.54 per share. 65,400
12/18/2018 Abingworth LLP
Director
53,492   Disposition at $7.43 per share. 397,445
12/17/2018 Abingworth LLP
Director
88,889   Disposition at $8.17 per share. 726,223
10/15/2018 Sujal Shah
Chief Executive Officer; Director
5,000   Acquisition at $9.9 per share. 49,500
08/29/2018 Daniel Menold
Vice President, Finance
5,000   Disposition at $13 per share. 65,000
08/29/2018 Daniel Menold
Vice President, Finance
5,000   Derivative/Non-derivative trans. at $5 per share. 25,000
07/27/2018 Sujal Shah
Chief Executive Officer; Director
5,000   Acquisition at $10.9 per share. 54,500
/news/latest/company/us/cbay

MarketWatch News on CBAY

  1. CymaBay Therapeutics stock price target raised to $6.00 from $1.50 at B. Riley FBR

    7:47 a.m. May 13, 2020

    - Tomi Kilgore

  2. CymaBay Therapeutics upgraded to buy from neutral at B. Riley FBR

    7:46 a.m. May 13, 2020

    - Tomi Kilgore

  3. CymaBay Therapeutics upgraded to buy from hold at Stifel Nicolaus

    8:05 a.m. May 12, 2020

    - Tomi Kilgore

  4. CymaBay Therapeutics upgraded to outperform from market perform at Raymond James

    8:00 a.m. May 12, 2020

    - Tomi Kilgore

  5. 13D Filings

    9:31 p.m. March 20, 2020

    - Barron's Online

  6. CymaBay Therapeutics upgraded to outperform from perform at Oppenheimer

    7:10 a.m. March 13, 2020

    - Tomi Kilgore

  7. 4 Smaller, Cash-Rich Biotech Stocks That Could Be Havens

    9:06 p.m. March 6, 2020

    - Barron's Online

  8. CymaBay Therapeutics downgraded to market perform vs. strong buy at Raymond James

    9:48 a.m. Nov. 26, 2019

    - Ciara Linnane

  9. CymaBay Therapeutics shares down 77% premarket after resuming trade following halt

    9:33 a.m. Nov. 25, 2019

    - Ciara Linnane

  10. CymaBay shares fall 77% on halted trial

    9:34 a.m. Nov. 25, 2019

    - Jaimy Lee

  11. CymaBay Therapeutics started at buy with $14 stock price target at Stifel Nicolaus

    7:45 a.m. June 25, 2019

    - Tomi Kilgore

  12. CymaBay Therapeutics stock price target cut to $7 from $11 at B. Riley FBR

    12:15 p.m. June 17, 2019

    - Tomi Kilgore

  13. CymaBay Therapeutics upgraded to strong buy from market outperform at Raymond James

    7:27 a.m. June 12, 2019

    - Tomi Kilgore

  14. CymaBay Therapeutics started at neutral with $9 stock price target at B. Riley FBR

    10:08 a.m. Feb. 6, 2019

    - Tomi Kilgore

  15. CymaBay Therapeutics reiterated as buy at SunTrust Robinson Humphrey

    8:46 a.m. Dec. 31, 2018

    - Ciara Linnane

  16. 4 charts to watch as tech stocks rebound

    12:18 p.m. Feb. 14, 2018

    - Harry Boxer

  17. CymaBay Therapeutics started at outperform with $35 stock price target at Evercore ISI

    8:40 a.m. Feb. 13, 2018

    - Tomi Kilgore

  18. Loading more headlines...
/news/nonmarketwatch/company/us/cbay

Other News on CBAY

  1. CymaBay: Live And Die By The FDA

    2:34 p.m. June 25, 2020

    - Seeking Alpha

  2. CymaBay Therapeutics (CBAY) Gets a Buy Rating from B.Riley FBR

    3:21 a.m. June 22, 2020

    - SmarterAnalyst

  3. Inventiva files for IPO

    5:01 p.m. June 19, 2020

    - Seeking Alpha

  4. CymaBay up 7% on new seladelpar data in bile duct disorder

    11:22 a.m. June 19, 2020

    - Seeking Alpha

  5. Genfit: Beaten Down But Not Dead

    9:55 p.m. June 18, 2020

    - Seeking Alpha

  6. New kid on the block in race for NASH drug

    5:34 p.m. June 15, 2020

    - Seeking Alpha

  7. 5 Top Stocks Up 100%+ in May With More Room to Run

    8:34 a.m. June 1, 2020

    - Zacks.com

  8. NVAX, UNIT, CHK and CRC among midday movers

    12:43 p.m. May 12, 2020

    - Seeking Alpha

  9. What Made B.Riley FBR Upgrade CymaBay Therapeutics’ Stock?

    12:24 p.m. May 12, 2020

    - SmarterAnalyst

  10. SPG, NVAX among premarket gainers

    9:16 a.m. May 12, 2020

    - Seeking Alpha

  11. What’s Next for CymaBay’s NASH Study

    9:10 a.m. May 12, 2020

    - 247WallSt.com

  12. Two upgrades for CymaBay after 'stunning' developments

    7:23 a.m. May 12, 2020

    - Seeking Alpha

  13. Loading more headlines...

At a Glance

CymaBay Therapeutics, Inc.

7575 Gateway Boulevard

Suite 110

Newark, California 94560

Phone

1 5102938800

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

N/A

Net Income

$-102.81M

Employees

60.00

/news/pressrelease/company/us/cbay

Press Releases on CBAY

  1. Month's Top Gainers: $CREX $PTLA $CBAY

    8:58 a.m. May 28, 2020

    - The Market Signal

  2. Upward Moving Stocks Of The Week: $SRNE $NVAX $CBAY

    10:39 a.m. May 18, 2020

    - The Market Signal

  3. Loading more headlines...
Link to MarketWatch's Slice.